Equities
  • Price (USD)16.50
  • Today's Change-0.17 / -1.02%
  • Shares traded286.18k
  • 1 Year change-31.52%
  • Beta--
Data delayed at least 15 minutes, as of Apr 18 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
SHL:ASX since
announced
Transaction
value
Labormedizinisches Zentrum Dr Risch AGAnnounced20 Mar 202420 Mar 2024Announced-3.95%131.77m
Pathology Watch IncAnnounced16 Nov 202316 Nov 2023Announced-13.87%130.00m
SYNLAB Suisse SAAnnounced26 Jun 202326 Jun 2023Announced-24.38%167.17m
MVZ Medical Laboratories Dusseldorf GmbHDeal completed26 Apr 202326 Apr 2023Deal completed-27.77%197.50m
Data delayed at least 20 minutes, as of Apr 19 2024 07:10 BST.

Institutional shareholders

0.01%Per cent of shares held by top holders
HolderShares% Held
Boston Common Asset Management LLCas of 31 Mar 202428.57k0.01%
RhumbLine Advisers LPas of 31 Dec 202314.94k0.00%
Yorktown Management & Research Co., Inc.as of 29 Feb 202413.20k0.00%
Altair Advisers LLCas of 30 Nov 20233.35k0.00%
PNC Investments LLCas of 31 Dec 20231.22k0.00%
GAMMA Investing LLCas of 31 Mar 2024578.000.00%
ShariaPortfolio, Inc.as of 04 Apr 2024399.000.00%
Front Row Advisors LLCas of 31 Dec 20230.000.00%
Cornerstone Planning Group LLCas of 31 Dec 20230.000.00%
First Horizon Advisors, Inc.as of 31 Dec 20230.000.00%
More ▼
Data from 30 Nov 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.